Multiple interactions between the alpha2C- and beta1-adrenergic receptors influence heart failure survival

BMC Medical Genetics

Volumn 9, Issue , 2008, Pages

  Kardia, Sharon L R ^a   Kelly, Reagan J ^a   Keddache, Mehdi A ^b   Aronow, Bruce J ^b   Grabowski, Gregory A ^b   Hahn, Harvey S ^c   Case, Karen L ^c   Wagoner, Lynne E ^c   Dorn II, Gerald W ^c,d   Stephen, B ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR ALPHA(2C); ALPHA 2 ADRENERGIC RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; EPISTASIS; FEMALE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEOTIDE SEQUENCE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; ADOLESCENT; AGED; COHORT ANALYSIS; GENETIC EPISTASIS; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MIDDLE AGED; ONSET AGE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; COHORT STUDIES; EPISTASIS, GENETIC; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-1; RISK FACTORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 57249084644     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-9-93     Document Type: Article

References (40)

1. Bristow MR: Why does the myocardium fail? Insights from basic science. Lancet 1998, 352(Suppl 1):SI8-14. 10.1016/S0140-6736(98)90311-7 9736474
2. Bristow MR: Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail 2000, 6:8-14. 10.1054/jcaf.2000.9501 10908093
3. Liggett SB: Beta-adrenergic receptors in tTe failing heart: the good, the bad, and the unknown. J Clin Invest 2001, 107:947-948. 199564 11306597 10.1172/JCI12774
4. Aggarwal A Esler MD Socratous F Kaye DM: Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol 2001, 37:1246-1251. 10.1016/ S0735-1097(01)01121-4 11300430
5. Hein L Altman JD Kobilka BK: Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999, 402:181-184. 10.1038/46040 10647009
6. Bristow MR Hershberger RE Port JD Minobe W Rasmussen R: Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989, 35:295-303. 2564629
7. Dorn GW II Molkentin JD: Manipulating cardiac contractility in heart failure: Data from mice and men. Circulation 2004, 109:150-158. 10.1161/ 01.CIR.0000111581.15521.F5 14734503
8. van Campen LC Visser FC Visser CA: Ejection fraction improvement by beta-blocker treatment in patients with heart failure: An analysis of studies published in the literature. Cardiovasc Pharmacol 1998, 32(Suppl 1):S31-S35. 9731693
9. Poole-Wilson PA Swedberg K Cleland JG Di Lenarda A Hanrath P Komajda M Lubsen J Lutiger B Metra M Remme WJ Torp-Pedersen C Scherhag A Skene A: Carvedilol Or Metoprolol European Trial Investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003, 362:7-13. 10.1016/ S0140-6736(03)13800-7 12853193
10. Packer M Fowler MB Roecker EB Coats AJS Katus HA Krum H Mohacsi P Rouleau JL Tendera M Staiger C Holcslaw TL Amann-Zalan I: DeMets DL for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199. 10.1161/01.CIR.0000035653.72855.BF 12390947
11. Mason DA Moore JD Green SA Liggett SB: A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999, 274:12670-12674. 10.1074/jbc.274.18.12670 10212248
12. Wagoner LE Craft LL Zengel P McGuire N Rathz DA Dorn GW Liggett SB: Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 2002, 144:840-846. 12422153
13. Johnson JA Zineh I Puckett BJ McGorray SP Yarandi HN Pauly DF: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003, 74:44-52. 10.1016/ S0009-9236(03)00068-7 12844134
14. Liggett SB Mialet-Perez J Thaneemit-Chen S Wever SA Greene SM Hodne D Nelson B Morrison J Domanski MJ Wagoner LE Abraham WT Anderson JL Carlquist JF Krause-Steinrauf HJ Lazzeroni LC Port JD Lavori PW Bristow MR: A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006, 103:11288-11293. 1523317 16844790 10.1073/pnas.0509937103
15. Bengtsson K Melander O Orho-Melander M Lindblad U Ranstam J Rastam L Groop L: Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001, 104:187-190. 11447084
16. Iwai C Akita H Kanazawa K Shiga N Terashima M Matsuda Y Takai E Miyamoto Y Shimizu M Kajiya T Hayashi T Yokoyama M: Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J 2003, 146:106-109. 10.1016/ S0002-8703(03)00110-8 12851615
17. Mialet Perez J Rathz DA Petrashevskaya NN Hahn HS Wagoner LE Schwartz A Dorn GW II Liggett SB: Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003, 9:1300-1305. 10.1038/nm930 14502278
18. Small KM Forbes SL Rahman FF Bridges KM Liggett SB: A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000, 275:23059-23064. 10.1074/jbc.M000796200 10801795
19. Neumeister A Charney DS Belfer I Geraci M Holmes C Sharabi Y Alim T Bonne O Luckenbaugh DA Manji H Goldman D Goldstein DS: Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics 2005, 15:143-149. 10.1097/01213011-200503000-00002 15861038
20. Small KM Wagoner LE Levin AM Kardia SL Liggett SB: Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002, 347:1135-1142. 10.1056/ NEJMoa020803 12374873
21. Lobmeyer MT Gong Y Terra SG Beitelshees AL Langaee TY Pauly DF Schofield RS Hamilton KK Herbert Patterson J Adams KF Jr Hill JA Aranda JM Jr Johnson JA: Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007, 17:277-282. 10.1097/FPC.0b013e3280105245 17496726
22. Small KM Mialet-Perez J Seman CA Theiss CT Brown KM Liggett SB: Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci USA 2004, 101:13020-13025. 516511 15319474 10.1073/pnas.0405074101
23. Small KM Mialet-Perez J Liggett SB: Genetic variation within the β1-adrenergic receptor gene results in haplotype-specific expression phenotypes. J Cardiovasc Pharmacol 2008, 51:106-110. 18209576
24. Weir BS: Genetic data analysis II: Methods for discrete population genetic data. Sunderland, MA: Sinauer Associates 1996
25. Parmar M Machin D: Survival Analysis:A practical approach Chichester: John Wiley & Sons 1995
26. Storey JD Tibshirani R: Statistical significance for genome-wide experiments. Proc Natl Acad Sci 2003, 100:9440-9445. 170937 12883005 10.1073/pnas.1530509100
27. Beer DG Kardia SL Huang CC Giordano TJ Levin AM Misek DE Lin L Chen G Gharib TG Thomas DG Lizyness ML Kuick R Hayasaka S Taylor JMG Iannettoni MD Orringer MB Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824. 12118244
28. Lee Wen-Chung: Searching for Disease-Susceptibility Loci by Testing for Hardy-Weinberg Disequilibrium in a Gene Bank of Affected Individuals. Am J Epimdeiol 2003, 158:397-400. 12936892 10.1093/aje/kwg150
29. Gilsbach R Brede M Beetz N Moura E Muthig V Gerstner C Barreto F Neubauer S Vieira-Coelho MA Hein L: Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction. Cardiovasc Res 2007, 75:728-737. 10.1016/ j.cardiores.2007.05.017 17597596
30. Manly KF: Reliability of statistical associations between genes and disease. Immunogenetics 2005, 57:549-558. 10.1007/s00251-005-0025-x 16086172
31. Stone M: Cross-validatory choice and assessment of statistical predictions. J Royal Statist Soc Series B 1974, 36:111-147.
32. Zhu J Hastie T: Classification of gene microarrays by penalized logistic regression. Biostatistics 2004, 5:427-443. 10.1093/biostatistics/kxg046 15208204
33. Ritchie MD Motsinger AA: Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. Pharmacogenomics 2005, 6:823-834. 10.2217/ 14622416.6.8.823 16296945
34. Gong R Liu Z Li L: Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: Interaction with environmental/clinical factors. Arthritis Rheum 2007, 56:1608-1617. 10.1002/art.22598 17469143
35. Larsen JE Pavey SJ Passmore LH Bowman RV Hayward NK Fong KM: Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007, 13:2946-2954. 10.1158/1078-0432.CCR-06-2525 17504995
36. Pohjanen E Thysell E Jonsson P Eklund C Silfver A Carlsson IB Lundgren K Moritz T Svensson MB Antti H: A multivariate screening strategy for investigating metabolic effects of strenuous physical exercise in human serum. J Proteome Res 2007, 6:2113-2120. 10.1021/pr070007g 17428078
37. Agranoff D Fernandez-Reyes D Papadopoulos MC Rojas SA Herbster M Loosemore A Tarelli E Sheldon J Schwenk A Pollok R Rayner CFJ Krishna S: Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006, 368:1012-1021. 10.1016/ S0140-6736(06)69342-2 16980117
38. Wood IA Visscher PM Mengersen KL: Classification based upon gene expression data: Bias and precision of error rates. Bioinformatics 2007, 23:1363-1370. 10.1093/bioinformatics/btm117 17392326
39. Mertens BJ De Noo ME Tollenaar RA Deelder AM: Mass spectrometry proteomic diagnosis: Enacting the double cross-validatory paradigm. J Comput Biol 2006, 13:1591-1605. 10.1089/cmb.2006.13.1591 17147482
40. Rathz DA Brown KM Kramer LA Liggett SB: Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002, 39:155-160. 10.1097/ 00005344-200202000-00001 11791000